Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antimycoplasmal activity of ofloxacin (DL-8280).

Literature DB >> 6573869

Antimycoplasmal activity of ofloxacin (DL-8280).

Abstract

Ofloxacin (DL-8280; (+/-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1- pipera-zinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid) showed a broader spectrum and a greater potency of antimycoplasmal activity than did pipemidic acid, norfloxacin, tetracyclines, and lincomycin, but was inferior to erythromycin. Its mycoplasmacidal potency against clinical isolates of Mycoplasma pneumoniae was also greater than that of other quinolones and tetracyclines.

Entities: Chemical

Mesh：

Substances：

Year: 1983 PMID： 6573869 PMCID： PMC184683 DOI： 10.1128/AAC.23.3.509

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

15 in total

1. MYCOPLASMA PNEUMONIAE INFECTIONS. CLINICAL AND EPIDEMIOLOGIC STUDIES.

Authors: J T GRAYSTON; E R ALEXANDER; G E KENNY; E R CLARKE; J C FREMONT; W A MACCOLL
Journal: JAMA Date: 1965-02-01 Impact factor: 56.272

2. Failure of antibiotic therapy in calves with mycoplasmal arthritis and pneumonia.

Authors: O H Stalheim
Journal: J Am Vet Med Assoc Date: 1976-11-15 Impact factor: 1.936

3. Immunoprophylaxis of experimental Mycoplasma pneumoniae disease: effect of route of administration on the immunogenicity and protective effect of inactivated M. pneumoniae vaccine.

Authors: H Greenberg; C M Helms; M B Grizzard; W D James; R L Horswood; R M Chanock
Journal: Infect Immun Date: 1977-04 Impact factor: 3.441

4. Comparison of antibiotics in the treatment of mycoplasmal pneumonia.

Authors: J M Shames; R B George; W B Holliday; J R Rasch; W J Mogabgab
Journal: Arch Intern Med Date: 1970-04

Review 5. Mycoplasma infections of man.

Authors: R M Chanock
Journal: N Engl J Med Date: 1965-11-25 Impact factor: 91.245

6. Mycoplasma pneumoniae pneumonia in an urban area. Five years of surveillance.

Authors: H M Foy; G E Kenny; R McMahan; A M Mansy; J T Grayston
Journal: JAMA Date: 1970-11-30 Impact factor: 56.272

7. Ecology of Mycoplasma pneumoniae infections in marine recruits at Parris Island, South Carolina.

Authors: P Steinberg; R J White; S L Fuld; R R Gutekunst; R M Chanock; L B Senterfit
Journal: Am J Epidemiol Date: 1969-01 Impact factor: 4.897

8. Hemolytic anemia. Associated with severe Mycoplasma pneumoniae pneumonia.

Authors: H B Tanowitz; N Robbins; N Leidich
Journal: N Y State J Med Date: 1978-12

9. Comparison of josamycin and erythromycin in the therapy of Mycoplasma pneumoniae pneumonia.

Authors: R P Wenzel; J O Hendley; W K Dodd; J M Gwaltney
Journal: Antimicrob Agents Chemother Date: 1976-12 Impact factor: 5.191

10. Naturally occurring and experimentally induced mycoplasmal arthritis of cattle.

Authors: O H Stalheim; L A Page
Journal: J Clin Microbiol Date: 1975-09 Impact factor: 5.948

21 in total

1. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.

Authors: G E Kenny; F D Cartwright
Journal: Antimicrob Agents Chemother Date: 1991-03 Impact factor: 5.191

Review 2. Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors: P A Todd; D Faulds
Journal: Drugs Date: 1991-11 Impact factor: 9.546

3. In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae.

Authors: K Izumikawa; Y Hirakata; T Yamaguchi; R Yoshida; H Tanaka; H Takemura; S Maesaki; K Tomono; M Kaku; K I Izumikawa; S Kamihira; S Kohno
Journal: Antimicrob Agents Chemother Date: 1998-03 Impact factor: 5.191

4. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors: J S Wolfson; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1985-10 Impact factor: 5.191

5. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan.

Authors: T Yamaguchi; Y Hirakata; K Izumikawa; Y Miyazaki; S Maesaki; K Tomono; Y Yamada; S Kamihira; S Kohno
Journal: Antimicrob Agents Chemother Date: 2000-05 Impact factor: 5.191

6. In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors: P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal: Antimicrob Agents Chemother Date: 1994-11 Impact factor: 5.191

7. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors: K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal: Antimicrob Agents Chemother Date: 1994-04 Impact factor: 5.191

8. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.

Authors: M Kaku; K Ishida; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal: Antimicrob Agents Chemother Date: 1994-04 Impact factor: 5.191

9. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors: K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal: Antimicrob Agents Chemother Date: 1991-06 Impact factor: 5.191

10. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.

Authors: Y Gohara; S Arai; A Akashi; K Kuwano; C C Tseng; S Matsubara; M Matumoto; T Furudera
Journal: Antimicrob Agents Chemother Date: 1993-09 Impact factor: 5.191